Edition:
United Kingdom

Dr.Reddy's Laboratories Ltd (REDY.NS)

REDY.NS on National Stock Exchange of India

2,751.30INR
22 Mar 2019
Change (% chg)

Rs-0.35 (-0.01%)
Prev Close
Rs2,751.65
Open
Rs2,779.00
Day's High
Rs2,779.00
Day's Low
Rs2,738.50
Volume
685,401
Avg. Vol
981,878
52-wk High
Rs2,878.00
52-wk Low
Rs1,872.95

Chart for

About

Dr. Reddy's Laboratories Limited is a pharmaceutical company that is engaged in providing medicines. The Company operates in three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment includes manufacturing and marketing prescription and... (more)

Overall

Beta: 0.11
Market Cap(Mil.): Rs394,104.81
Shares Outstanding(Mil.): 165.88
Dividend: 20.00
Yield (%): 0.84

Financials

  REDY.NS Industry Sector
P/E (TTM): 32.79 29.30 32.54
EPS (TTM): 72.46 -- --
ROI: -- 14.23 13.82
ROE: -- 15.46 15.25

UPDATE 1-Indian drugmaker Dr. Reddy's Q3 profit surges on strong growth in emerging markets

Feb 1 Indian generic drugmaker Dr. Reddy's Laboratories Ltd posted a 65.3 percent surge in quarterly profit on Friday, handily beating market expectations, helped by strong growth in emerging markets.

01 Feb 2019

Indian drugmaker Dr. Reddy's Q3 profit rises 65.3 pct, beats estimates

Feb 1 Indian generic drugmaker Dr. Reddy's Laboratories Ltd posted a 65.3 percent surge in quarterly profit on Friday, driven by strong growth in emerging markets.

01 Feb 2019

Indivior plans cheaper opioid addiction drug if rivals launch copycats

Indivior Plc said on Tuesday it could launch a cheaper version of its blockbuster opioid addiction treatment, Suboxone, if rivals release generic versions of the drug.

18 Dec 2018

UPDATE 2-Cost cuts help drugmaker Indivior as it battles cheap rival

* Shares give back early gains to trade lower (Adds details on the company's drugs, background, comments)

01 Nov 2018

UPDATE 1-Indian drugmaker Dr. Reddy's Q2 profit soars past market estimates

Oct 26 Dr.Reddy's Laboratories posted a better-than-expected rise in second-quarter profit as higher sales in some emerging countries offset a marginal decline in business in North America, a key market for the Indian generic drugmaker.

26 Oct 2018

Earnings vs. Estimates